The developer of a rival weight-loss treatment to those offered by Novo Nordisk and Eli Lilly said its drug had achieved positive results in liver disease trials, showing how a new class of obesity drugs can offer wider health benefits.
Privately held German pharma group Boehringer Ingelheim and Zealand Pharma’s survodutide treatment had a “statistically significant improvement” for 83 per cent of patients with metabolic dysfunction-associated steatohepatitis (MASH), compared with a placebo, after a 48-week, mid-stage trial.
Shares in Copenhagen-listed Zealand Pharma rose 26 per cent on Monday morning. The drug is also in late-stage trials for obesity treatment.
您已阅读20%（668字），剩余80%（2757字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。